Baxter considers sale of kidney care unit to PE firm: WSJ
Dive Brief: Baxter is considering the sale of its kidney care business to private equity firm Carlyle Group for more than $4 billion, The Wall
Dive Brief: Baxter is considering the sale of its kidney care business to private equity firm Carlyle Group for more than $4 billion, The Wall
Dive Brief: The Food and Drug Administration is expanding a program for accelerating device development to cover neurological and physical medicine technologies. Initially, the voluntary
A class of synthetic opioids known as the nitazenes that are as potent as fentanyl — or stronger — have been increasingly involved in deaths